# LUX-Lung 6 (NCT01121393)

> BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

- Drugs tested: afatinib
- Indication: EGFR mutation-positive advanced lung adenocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01121393
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Boehringer Ingelheim
- Conditions: Carcinoma, Non-Small-Cell Lung; Adenocarcinoma
- Interventions: Gemcitabine+Cisplatin; BIBW 2992
- Enrollment: 364
- Primary outcome: Progression-free Survival

## Indexed commentary on LUX-Lung 6 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 6 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=lux-lung-6-nct01121393
